Welcome to our dedicated page for Morphosys news (Ticker: MPSYF), a resource for investors and traders seeking the latest updates and insights on Morphosys stock.
Morphosys AG (MPSYF) is a global biopharmaceutical leader specializing in therapeutic antibody development through its proprietary hucal® technology. This page provides investors and industry professionals with essential updates on corporate developments, research milestones, and regulatory progress.
Our curated news collection offers immediate access to official press releases, including updates on clinical trials, strategic partnerships, and financial performance. Track the company's progress across key therapeutic areas such as oncology and autoimmune diseases through verified information sources.
Regular updates cover critical developments including FDA submissions, collaboration announcements with major pharmaceutical companies, and pipeline expansion details. All content is maintained to reflect Morphosys' position at the forefront of antibody-based therapies without speculative commentary.
Bookmark this page for streamlined access to Morphosys' evolving story in biopharmaceutical innovation. Check back regularly for authoritative updates directly impacting the company's trajectory in precision medicine development.
MorphoSys AG announced that shareholders approved all resolutions at its 2024 Annual General Meeting, including a merger squeeze-out of minority shareholders. The key points are:
1. Minority shareholders' shares will be transferred to Novartis BidCo Germany AG, the majority shareholder.
2. Cash compensation set at €68.00 per share.
3. The squeeze-out becomes effective upon registration in commercial registers of both MorphoSys and Novartis.
4. The virtual meeting had 92.43% representation of MorphoSys' share capital.
5. All proposed resolutions by the Management Board and Supervisory Board were approved.
Novartis BidCo Germany AG has announced its intention to merge MorphoSys AG into Novartis BidCo Germany AG, a move that includes a merger squeeze-out of MorphoSys AG's minority shareholders. The company holds approximately 91.04% of MorphoSys AG's share capital, qualifying it as the majority shareholder under German law. Novartis BidCo Germany AG has proposed negotiations with the MorphoSys AG Management Board to finalize the merger agreement and has submitted a formal request to initiate the process to transfer the minority shareholders' shares against adequate cash compensation. The necessary resolution is expected to be adopted at the MorphoSys AG Annual General Meeting in August 2024. The cash compensation amount for minority shareholders is yet to be determined.
FAQ
What is the current stock price of Morphosys (MPSYF)?
What is the market cap of Morphosys (MPSYF)?
